| Rich66 |
04-22-2010 12:20 PM |
Zen and the art of Cancer Research at #AACR10
LINK
Quote:
Here are some quick thoughts of the top of my head:
- The cancer genome is now dominant and understanding the biology is very much a focus, even from manufacturers.
- Free plasma DNA is going to be critical for biomarker research.
- RNA seems appear in almost every other abstract (more later).
- GWAS is becoming more relevant, highlighting distinct subsets of patients who can then be evaluated for prognosis, biomarkers, efficacy and tolerability differences.
- Combination targeted therapy is the smart way to go to eliminate cross-talk, feedback and feedforward loops. They may also reduce some acquired resistance, at least for a time.
- Dr Bert Vogelstein noted that there are currently 12 critical pathways that impact cancer cell survival. Understanding these more will lead to new and better therapies.
- Despite all the above, cancer is a heterogeneous disease and much work still needs to be done in unravelling the mysteries behind it.
|
.................................................. .......
|
